{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:07:02Z","timestamp":1789164422868,"version":"build-2803163510"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rofo"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Patients with Alzheimer\u2019s disease (AD) can now be treated with monoclonal antibodies aiming at clearing amyloid plaques from the brain parenchyma. Weeks after initiation of this drug therapy, patients may develop so-called amyloid-related imaging abnormalities (ARIA) on MRI. ARIA comprise vasogenic edema and leptomeningeal effusions (ARIA-E) as well as microbleeds and superficial hemosiderosis (ARIA-H). The prevalence is drug- and dose-dependent (up to 40\u200a% of patients), the apolipoprotein E4 variant and concomitant cerebral amyloid angiopathy (CAA) increase the risk. With regard to MRI characteristics, ARIA strongly resembles the so-called inflammatory subtype of CAA (CAA-ri). While patients with CAA-ri are typically detected due to symptoms such as headaches, lethargy, confusion, and rarely epileptic seizures, around 20\u200a% of ARIA patients show symptoms. Management of ARIA is not yet clearly established. In asymptomatic patients, discontinuation of the drug might be sufficient.<\/jats:p><jats:p>\n            Key points\u2002<\/jats:p><jats:p>\n            Citation Format\n          <\/jats:p>","DOI":"10.1055\/a-2185-8472","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T23:43:45Z","timestamp":1700783025000},"page":"363-369","source":"Crossref","is-referenced-by-count":10,"title":["Imaging of Amyloid-Related Imaging Abnormalities (ARIA)"],"prefix":"10.1055","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-4807","authenticated-orcid":false,"given":"Horst","family":"Urbach","sequence":"additional","affiliation":[{"name":"Dept. of Neuroradiology, University Medical Center Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Linn","sequence":"additional","affiliation":[{"name":"Dept. of Neuroradiology, University Medical Center Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hattingen","sequence":"additional","affiliation":[{"name":"Dept. of Neuroradiology, University Medical Center Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Fiebach","sequence":"additional","affiliation":[{"name":"CSB-Neuroradiology, Charite University Hospital Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"ref2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/jnnp.73.4.390","article-title":"Potentially reversible conditions in 1000 consecutive memory clinic patients","volume":"73","author":"A Hejl","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.nicl.2018.09.013","article-title":"Voxel-wise deviations from healthy aging for the detection of region-specific atrophy","volume":"20","author":"S Kl\u00f6ppel","year":"2018","journal-title":"Neuroimage Clin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/a-1125-7455","article-title":"MRT bei neurodegenerativen Erkrankungen","volume":"88","author":"H Urbach","year":"2020","journal-title":"Fortschritte der Neurologie Psychiatrie"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1240514","article-title":"Garbage Truck of the Brain","volume":"340","author":"M Nedergaard","year":"2013","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","author":"C H van Dyck","year":"2022","journal-title":"NEJM"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"W J Jansen","year":"2015","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/ene.14031","article-title":"Nationwide survey of cerebral amyloid angiopathy in Japan","volume":"26","author":"K Sakai","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00415-008-0674-4","article-title":"Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy. An autopsy study","volume":"255","author":"J Attems","year":"2008","journal-title":"Journal of Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2990.2010.01137.x","article-title":"Review: Sporadic cerebral amyloid angiopathy","volume":"37","author":"J Attems","year":"2011","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ana.25512","article-title":"Different microvascular alterations underlie microbleeds and microinfarcts","volume":"86","author":"S J van Veluw","year":"2019","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/STROKEAHA.117.016990","article-title":"Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria","volume":"49","author":"S M Greenberg","year":"2018","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fneur.2012.00133","article-title":"Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk","volume":"3","author":"A Charidimou","year":"2012","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis","volume":"18","author":"L Jakel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","article-title":"Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy","volume":"74","author":"J Linn","year":"2010","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","volume":"21","author":"A Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","article-title":"Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation","volume":"73","author":"E Auriel","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref20","first-page":"682","article-title":"[Cerebral amyloid angiopathy associated with inflammation]","volume":"89","author":"J Schaumberg","year":"2018","journal-title":"Nervenarzt"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/brain\/awh379","article-title":"A\u03b2-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy","volume":"128","author":"N J Scolding","year":"2005","journal-title":"Brain"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease \u2013 one peptide, two pathways","volume":"16","author":"S M Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000260066.98681.2e","article-title":"Course of cerebral amyloid angiopathy-related inflammation","volume":"68","author":"C Kinnecom","year":"2007","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.brainres.2019.04.014","article-title":"Impaired dynamic cerebral autoregulation in patients with cerebral amyloid angiopathy","volume":"1717","author":"M Reinhard","year":"2019","journal-title":"Brain Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature22809","article-title":"Addendum: The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"546","author":"J Sevigny","year":"2017","journal-title":"Nature"},{"key":"ref27","first-page":"146","article-title":"The future of Anti-Amyloid trials","volume":"7","author":"P S Aisen","year":"2020","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"J Cummings","year":"2020","journal-title":"Alzheimers Dement (NY)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer\u2019s Disease Therapeutics","author":"J Cummings","year":"2023","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-Related Imaging Abnormalities: An Update","volume":"220","author":"M Roytman","year":"2023","journal-title":"Am J Roentgenol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"R A Sperling","year":"2011","journal-title":"Alzheimer Dement"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR Imaging Features of Amyloid-Related Imaging Abnormalities","volume":"34","author":"J Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion","volume":"34","author":"F Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"e12376","DOI":"10.1002\/dad2.12376","article-title":"Comparing ARIA-E severity scales and effects of treatment management thresholds","volume":"14","author":"G Klein","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"S Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid-Targeting Antibodies: A Systematic Review","volume":"79","author":"M Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref37","first-page":"e12101","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54\/\u03b54 patient treated with aducanumab","volume":"12","author":"L VandeVrede","year":"2020","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke","volume":"388","author":"N J Reish","year":"2002","journal-title":"N Engl J Med"}],"container-title":["R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2185-8472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:13:01Z","timestamp":1730815981000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2185-8472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":35,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2185-8472","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1438-9029","1438-9010"],"issn-type":[{"value":"1438-9029","type":"print"},{"value":"1438-9010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}